UCLA Medical Center of Hematology/Oncology
Los Angeles, CA
Filters
Save & Share
Clear Filters
Diagnosis
Treatment History
BCMA Therapy
This stands for B Cell Maturation Antigen (BCMA) and includes treatments such as ide-cel, cilta-cel or belantamab mafodotin.
Accepting patients
QUINTESSENTIAL
Phase 2 Study of BMS-986393, a GPRC5D-directed CART-Cell Therapy, in Participants with Relapsed or Refractory Multiple Myeloma
Learn more- CAR T Cell
- GPRC5D
- Phase 2
Accepting patients
LINKER-MM3
A Trial to Learn How Well Linvoseltamab works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants with Relapsed/Refractory Multiple Myeloma
Learn more- Bispecific Antibody
- BCMA
- Randomization
- Phase 3
Accepting patients
LINKER-MM4
Phase 1/2 Study of Linvoseltamab (Anti-BCMA X Anti-CD3 Bispecific Antibody) in Previously Untreated Patients With Symptomatic Multiple Myeloma
Learn more- Bispecific Antibody
- BCMA
- Phase 1/2
Accepting patients
BMF-219
A Phase 1 First-in-human Dose-escalation and Dose-expansion Study of BMF-219, an Oral Covalent Menin Inhibitor, in Adult Patients With Acute Leukemia (AL), Diffuse Large B-cell Lymphoma (DLBCL), Multiple Myeloma (MM), and Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL)
Learn more- Menin Inhibitor
- Phase 1